Mycophenolate Mofetil in Anti-Neutrophil Cytoplasm Antibodies-Associated Systemic Vasculitis
Authors:
- David R.W. JayneDJDavid R.W. Jayne
- 15 November 2005
- journal article
- Published by S. Karger AG in Nephron Clinical Practice
- Vol. 102 (3-4) , c100-c107
Abstract
Background: Mycophenolate mofetil (MMF) is an immune suppressive initially introduced for the prevention of solid organ allograft rejection that is increasingly used in autoimmune conditions, including vasculitis. Methods: This retrospective study evaluated the efficacy and tolerability of MMF in 51 sequential patients with anti-neutrophil cytoplasm antibodies-associated systemic vasculitis (AASV) treated in a single centre between 2001 and 2004. Results: The mean age was 54 years and median disease duration was 36 months. A mean of 3.5 systems were involved and the previous median exposure to cyclophosphamide was 9 g. MMF was administered either as remission maintenance therapy (29/51, 56.9%) or as treatment for active disease (22/51, 43.1%). The mean duration of MMF therapy was 20 months and the mean MMF dose during the first year was 1.6 g/day. 14/29 (48.3%) of those receiving MMF for remission maintenance therapy eventually relapsed with a mean time to relapse of 14 months. Of those receiving MMF for relapsing disease, 3 failed to respond to therapy while the rest achieved remission by 3.9 months. However, 9 of these subsequently flared; mean time to disease flare was also 14 months. MMF was withdrawn in 28 patients (54.9%) because of treatment inefficacy in 21, severe adverse events in 5 and intolerance in 2. Of the 51 treated, 36 (70.6%) experienced at least 1 side effect, namely infections in 24, gastrointestinal side effects in 12 and psychological events in 6 patients. Conclusions: We have observed varying efficacy of MMF in AASV, with over 50% of patients with relapsing disease achieving remission and marked falls in concomitant steroid doses. However, longer follow-up indicates a subsequent relapse rate of over 50% that may be associated with low MMF dosing.Keywords
This publication has 18 references indexed in Scilit:
- Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody–associated vasculitisArthritis & Rheumatism, 2005
- Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosisArthritis Care & Research, 2004
- Prospective Study of TNFα Blockade with Infliximab in Anti-Neutrophil Cytoplasmic Antibody-Associated Systemic VasculitisJournal of the American Society of Nephrology, 2004
- Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at riskAnnals of the Rheumatic Diseases, 2003
- Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration1Transplantation, 2003
- 15-Deoxyspergualin in Patients with Refractory ANCA-Associated Systemic VasculitisJournal of the American Society of Nephrology, 2003
- High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low‐dose methotrexateArthritis Care & Research, 2002
- Mycophenolate mofetil treatment for primary glomerular diseasesKidney International, 2002
- Nomenclature of Systemic VasculitidesArthritis & Rheumatism, 1994
- Long-term remission of intractable systemic vasculitis with monoclonal antibody therapyThe Lancet, 1993